N-glycosides Wherein The N Is Part Of A Five-membered Hetero Ring (e.g., Selenazole Nucleosides, Pyrrole Nucleosides, Etc.) Patents (Class 536/28.6)
Plural nitrogens in the n-hetero ring (e.g., triazoles, etc.) (Class 536/28.7)
  • Moncyclic L-nucleosides analogs
    Patent number: 6552183
    Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: April 22, 2003
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
  • Treatment of viral infections using the L-isomer of ribavirin
    Patent number: 6518253
    Abstract: A 1-(&bgr;-L-ribofuranosyl)-1,2,4-triazole-3-carboxamide is administered in a method of treatment of a viral infection in a patient, including HIV infection, HCV infection, or BHV infection.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: February 11, 2003
    Inventor: Robert Tam
  • Preparation and isolation of indolocarbazole glycosides
    Publication number: 20020193324
    Abstract: The present invention relates to a novel process to make indolocarbazole glycosides in high purity which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Application
    Filed: March 21, 2002
    Publication date: December 19, 2002
    Inventors: Steven Weissman, David Tschaen, Asayuki Kamatani, Shouichi Hiraga, Masashi Kawasaki, Takehiko Iida
  • Nucleoside compounds
    Patent number: 6495677
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: December 17, 2002
    Inventors: Kanda S. Ramasamy, Guangyi Wang, Johnson Lau
  • Tumor proliferation inhibitors
    Publication number: 20020068705
    Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.
    Type: Application
    Filed: September 25, 2001
    Publication date: June 6, 2002
    Inventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
  • Phase transfer catalyzed glycosidation of an indolocarbazole
    Publication number: 20020058803
    Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.
    Type: Application
    Filed: October 22, 2001
    Publication date: May 16, 2002
    Inventors: Daniel E. Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen